AstraZeneca PLC (AZN)vsInnovative Eyewear Inc. (LUCY)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
LUCY
Innovative Eyewear Inc.
$1.05
+0.96%
HEALTHCARE · Cap: $6.49M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2206723% more annual revenue ($58.74B vs $2.66M). AZN leads profitability with a 17.4% profit margin vs -285.2%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
LUCY
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+39.2%
Fair Value
$1.81
Current Price
$1.05
$0.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Revenue surging 39.0% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -83.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : LUCY
The strongest argument for LUCY centers on Price/Book, Revenue Growth. Revenue growth of 39.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : LUCY
The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while LUCY is a hypergrowth play — different risk/reward profiles.
LUCY carries more volatility with a beta of 3.06 — expect wider price swings.
LUCY is growing revenue faster at 39.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 36/100), backed by strong 17.4% margins. LUCY offers better value entry with a 39.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Innovative Eyewear Inc.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Innovative Eyewear Inc. (LUCY) is a pioneering player in the smart eyewear sector, skillfully merging advanced technology with modern aesthetics to meet the needs of tech-savvy consumers. Its flagship line, Lucyd, stands out by integrating audio features and connectivity into stylish eyewear, thus providing both versatility and fashion. With a strong focus on innovation and enhancing user experiences, the company is well-positioned to harness the growing demand for multifunctional wearables, indicating significant growth potential in the rapidly evolving eyewear market. As trends shift towards smart solutions, LUCY's strategic approach positions it favorably for long-term success.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?